A multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: A Korean Radiation Oncology Group study (KROG 13-17)

作者：Yoon Mee Sun; Park Won^*; Huh Seung Jae; Kim Hak Jae; Kim Young Seok; Kim Yong Bae; Kim Joo Young; Lee Jong Hoon; Kim Hun Jung; Cha Jihye; Kim Jin Hee; Kim Juree; Yoon Won Sup; Choi Jin Hwa; Chun Mison; Choi Youngmin; Chang Sei Kyung; Lee Kang Kyoo; Kim Myungsoo

来源：Gynecologic Oncology, 2015, 138(3): 519-525.

DOI：10.1016/j.ygyno.2015.06.030

• Endometrial cancer
• Adjuvant radiotherapy
• Adjuvant chemoradiotherapy

Objective. To investigate whether combined chemoradiotherapy (CTRT) confers a benefit for survival outcome over radiotherapy (RT) alone after primary surgery in patients with FIGO stage IIIC endometrial adenocarcinoma.
Methods. We conducted a multicenter retrospective study of patients with surgical stage IIIC endometrial cancer from 1990 to 2011. Adjuvant RT alone was performed in 85 patients (403%) and adjuvant CTRT in 126 patients (59.7%). Disease-free survival (DFS) and overall survival (OS) were analyzed using Kaplan-Meier method and Cox proportional hazards model.
Results. Stage 1110 and stage IIIC2 accounted for 63% and 37%, respectively. FIGO IIIC2 had a higher recurrence rate than FIGO IIIC1 (38.5% vs. 293%, p = 0.172). Five-year OS and DFS were lower in FIGO IIIC2 than FIGO IIIC1 (85.1% vs. 76.9%, p = 0.417; 71.0% vs. 59.2%, p = 0.108, respectively). Eighteen patients (13.5%) in stage IIIC1 developed PALN recurrence, whereas only one (3.3%) in stage IIIC2 had PALN recurrence (p = 0.001). In multivariate analysis, predictors of DFS were parametrial invasion (HR, 3.49; 95% CI, 1.83-6.64; p < 0.001), higher grade (HR, 2.78; 95% CI, 1.31-5.89; p = 0.008), and >3 positive pelvic nodes (HR, 1.84; 95% CI, 1.11-3.05; p = 0.019). Combined CTRT did not affect DFS or OS in IIIC1 and IIIC2 compared with RT alone.
Conclusion. CTRT showed comparable survival outcome to RT alone. Half of relapses (46%) in stage IIIC1 occurred in PALN region, whereas relapse in stage IIIC2 primarily occurred in distant metastasis (90%). Future randomized studies are needed to determine which subgroup may be most likely to benefit from CCRT.

• 出版日期2015-9